A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.

A pH-sensitive dual-targeting drug carrier (G4-DOX-PEG-Tf-TAM) was synthesized with transferrin (Tf) conjugated on the exterior and Tamoxifen (TAM) in the interior of the fourth generation PAMAM dendrimers for enhancing the blood-brain barrier (BBB) transportation and improving the drug accumulation in the glioma cells. It was found that, on average, 7 doxorubicine (DOX) molecules, over 30 PEG(1000) and PEG(2000) chains and one Tf group were bonded on the periphery of each G4 PAMAM dendrimer, while 29 TAM molecules were encapsulated into the interior of per dendrimer. The pH-triggered DOX release was 32% at pH 4.5 and 6% at pH 7.4, indicating a comparatively fast drug release at weak acidic condition and stable state of the carrier at physiological environment. The in vitro assay of the drug transport across the BBB model showed that G4-DOX-PEG-Tf-TAM exhibited higher BBB transportation ability with the transporting ratio of 6.06% in 3 h. The carrier was internalized into C6 glioma cells upon crossing the BBB model by the coactions of TfR-mediated endocytosis and the inhibition effect of TAM to the drug efflux transports. Moreover, it also displayed the in vitro accumulation of DOX in the avascular C6 glioma spheroids made the tumor volume effectively reduced.

[1]  E. Meijer,et al.  The dendritic box, shape-selective liberation of encapsulated guests , 1995 .

[2]  Donald A Tomalia,et al.  Dendrimers in biomedical applications--reflections on the field. , 2005, Advanced drug delivery reviews.

[3]  Sagar Agarwal,et al.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain , 2011, Expert Reviews in Molecular Medicine.

[4]  F. Szoka,et al.  PEGylated dendrimers with core functionality for biological applications. , 2008, Bioconjugate chemistry.

[5]  R. Kannan,et al.  Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.

[6]  Yan Zhang,et al.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  M. Glatzel,et al.  Efficient Chemotherapy of Rat Glioblastoma Using Doxorubicin-Loaded PLGA Nanoparticles with Different Stabilizers , 2011, PloS one.

[8]  A. Chilkoti,et al.  Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[9]  W. Jefferies,et al.  Transferrin receptor on endothelium of brain capillaries , 1984, Nature.

[10]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[11]  T. Young,et al.  Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Rongrong Hua,et al.  Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. , 2010, Molecular pharmaceutics.

[13]  Yang Yang,et al.  A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[14]  R. Goodman,et al.  Tamoxifen Paradoxically Decreases Paclitaxel Deposition into Cerebrospinal Fluid of Brain Tumor Patients , 2005, Journal of Neuro-Oncology.

[15]  W. Hall Transferrin receptor on glioblastoma multiforme. , 1991, Journal of Neurosurgery.

[16]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[17]  D. V. Kohli,et al.  Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil , 2005, Journal of drug targeting.

[18]  Mark W Grinstaff,et al.  Biomedical applications of dendrimers: a tutorial. , 2011, Chemical Society reviews.

[19]  A. Ballangrud,et al.  Binding and interstitial penetration of liposomes within avascular tumor spheroids , 2004, International journal of cancer.

[20]  E. Simanek,et al.  Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. , 2007, Polymer international.

[21]  Yan Zhang,et al.  Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  W. Pardridge,et al.  Drug and gene targeting to the brain with molecular trojan horses , 2002, Nature Reviews Drug Discovery.

[23]  Yan Zhang,et al.  Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. , 2009, Molecular pharmaceutics.

[24]  Javed Ali,et al.  Strategy for effective brain drug delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  K. Plate,et al.  Vascularization of human glioma spheroids implanted into rat cortex is conferred by two distinct mechanisms , 1999, Journal of neuroscience research.

[26]  R. Kayyali,et al.  Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells? , 1994, FEBS letters.

[27]  Y. Pei,et al.  Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. , 2010, Biomaterials.

[28]  A. Salgado,et al.  Dendrimers and derivatives as a potential therapeutic tool in regenerative medicine strategies—A review , 2010 .

[29]  Hall Wa Transferrin receptor on glioblastoma multiforme. , 1991 .

[30]  Seung Jin Lee,et al.  Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[31]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[32]  Mark W Grinstaff,et al.  Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. , 2006, Cancer research.

[33]  J. Benoit,et al.  Brain targeting using novel lipid nanovectors. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[35]  P. Hildgen,et al.  Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. , 2008, Molecular pharmaceutics.

[36]  C. Ferretti,et al.  Tamoxifen counteracts estradiol induced effects on striatal and hypophyseal dopamine receptors. , 1988, Life sciences.

[37]  W. Zhong,et al.  Shell cross-linked and hepatocyte-targeting nanoparticles containing doxorubicin via acid-cleavable linkage. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[38]  Z. Qian,et al.  Transferrin/transferrin receptor-mediated drug delivery. , 2002, Medicinal research reviews.

[39]  S. Kannan,et al.  Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. , 2009, Biomaterials.

[40]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[41]  P. Pávek,et al.  Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents , 2006, Epilepsia.

[42]  Kostas Kostarelos,et al.  Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. , 2008, Small.

[43]  E. Simanek,et al.  Reduction of drug toxicity using dendrimers based on melamine. , 2004, Molecular pharmaceutics.

[44]  Whelan NAALADase inhibitors: A novel approach to glutamate regulation. , 2000, Drug discovery today.

[45]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Robert,et al.  Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance , 2005, Journal of Cancer Research and Clinical Oncology.

[47]  Xue Ying,et al.  PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. , 2011, Biomaterials.

[48]  H. Sarin Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors , 2009, Journal of Translational Medicine.